Pentosan Polysulfate (PPS)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Pentosan Polysulfate (PPS) is listed as regenerative / glycosaminoglycan analog.
- •Interstitial cystitis
- •Osteoarthritis (off-label)
- •Cartilage protection
Regulatory status: FDA-Approved for IC; veterinary approved; off-label orthopedic use.
Structure & Properties
Compound: Pentosan Polysulfate (PPS); also known as Elmiron, Cartrophen.
Pharmacologic class: Regenerative / Glycosaminoglycan Analog.
Known delivery routes: Oral, Intramuscular.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Synthetic glycosaminoglycan analog — inhibits MMP enzymes; stimulates proteoglycan synthesis; anti-inflammatory; anti-fibrotic; supports synovial fluid quality.
- •Bladder pain relief in IC
- •Possible joint/cartilage support
- •Anti-inflammatory
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Phase II cartilage trials (Arthrogen); FDA approved IC only.
Laboratory Research
Phase II cartilage trials (Arthrogen); FDA approved IC only
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Oral 100 mg 3× daily on an empty stomach (1 hr before or 2 hrs after meals).
Potential interactions and combinations to avoid
- •Concurrent anticoagulants — bleeding risk
- •Pentosan-associated maculopathy — annual eye exams
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Macular pigment changes with chronic oral use
- •Bleeding risk (anticoagulant)
- •Alopecia
Contraindications
- •Active bleeding disorders
- •Pregnancy
- •Retinal disease (caution)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Pre-existing maculopathy or retinal pigmentary changes (pigmentary maculopathy risk)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100 mg TID (oral); 2 mg/kg IM (injection)
Frequency: 3× daily (oral); weekly (IM)
Cycling: Continuous oral for IC; injectable orthopedic cycles vary.
Oral
For peptides formulated with absorption enhancers (SNAC) or small stable molecules.
Tablet or capsule. Swallow whole with ≤120 mL plain water, on an empty stomach. Wait 30 min before food, other meds, or additional liquid (bioavailability collapses otherwise).
Intramuscular (IM)
Used for depot formulations, some GH secretagogues (localized delivery), and clinical protocols requiring faster systemic uptake.
23–25G × 1–1.5" needle. 1–3 mL syringe. Ventrogluteal, vastus lateralis, or deltoid. Insert 90°, aspirate (optional), inject slowly. Rotate sites weekly.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Standard interstitial cystitis multimodal care
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Pentosan Polysulfate (PPS)?
In plain words
PPS is a man-made compound similar to substances found in the body's connective tissues. It slows enzymes that break down tissue and helps the body make materials that support cartilage and joint fluid. It is approved for interstitial cystitis [a bladder condition] and is studied for osteoarthritis, which is not an FDA-approved use. Clinical trial evidence is limited, and risks include bleeding, hair loss, and changes in the retina [the light-sensing tissue in the eye] with long-term oral use.
Technical definition
Pentosan polysulfate (PPS; also known as Elmiron or Cartrophen) is a synthetic glycosaminoglycan analog that inhibits matrix metalloproteinase (MMP) enzymes, stimulates proteoglycan synthesis, and supports synovial fluid quality, with anti-inflammatory and anti-fibrotic activity. It is FDA-approved for interstitial cystitis and has veterinary approvals; orthopedic use, including for osteoarthritis, is off-label, with limited randomized controlled trial evidence. Risks include macular pigment changes with chronic oral use, anticoagulant-related bleeding, and alopecia.
Function
Dosing
Recommended Time of Day
Any consistent time, 1× weekly (injectable) or with water 1 hr before meals (oral).
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Ventrogluteal — Palm on greater trochanter, index to ASIS — inject in the V. Safest IM site.
- Dorsogluteal (upper outer) — Upper outer quadrant of the buttock. Used for depot IM; alternate sides each cycle.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
- Anterior thigh (vastus lateralis) — Middle third of the outer front thigh. Preferred IM site for self-injection.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous oral for IC; injectable orthopedic cycles vary.
Timing & Interactions
- ·Concurrent anticoagulants — bleeding risk
- ·Pentosan-associated maculopathy — annual eye exams
- ·Standard interstitial cystitis multimodal care
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Pentosan Polysulfate (PPS) and sync them to Vial Lab.
Benefits
- ·Bladder pain relief in IC
- ·Possible joint/cartilage support
- ·Anti-inflammatory
Risks
- ·Macular pigment changes with chronic oral use
- ·Bleeding risk (anticoagulant)
- ·Alopecia
Contraindications
- ·Active bleeding disorders
- ·Pregnancy
- ·Retinal disease (caution)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Pre-existing maculopathy or retinal pigmentary changes (pigmentary maculopathy risk)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved for IC; veterinary approved; off-label orthopedic use
Veterinary Use (Pets)
No established veterinary protocol for Pentosan Polysulfate (PPS). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.